Pancreatic fistula may occur as a complication of chronic pancreatitis [1–3]. However, a communicating fistula between the pancreatic ductal system and the portal vein is a rare and difficult-to-treat complication [4].

We present the first report of endoscopic ultrasound (EUS)-guided main pancreatic duct rendezvous treatment of a symptomatic case of pancreaticoportal fistula. The case was complicated by a partial portal vein thrombosis, related to a pancreatic pseudocyst from chronic pancreatitis.

A 69-year-old man presented with abdominal pain and weight loss during the previous 6 months. Laboratory tests revealed anemia (hemoglobin 7.7 g/dL) an increased amylase (7759 U/L) and an albumin of 3.4 g/L. Clinical history and abdominal magnetic resonance imaging (MRI) led to a diagnosis of pancreatic pseudocyst related to underlying alcoholic chronic pancreatitis. The MRI further showed a dilatation of the portal vein related to partial thrombosis (Fig. 1).

We performed an endoscopic retrograde pancreatography (ERP) that revealed a cystic collection in the head of the pancreas with stenosis and dilatation of the main pancreatic duct and secondary ducts. We were unable to pass a guidewire through the pancreatic duct stricture (Fig. 2). However, it was passed through a pancreaticoportal fistula, and the portal vein was visualized immediately after contrast injection.

We then attempted an EUS-guided rendezvous maneuver. We accessed the main pancreatic duct through the stomach with a 19G needle, obtained pancreatography, and passed a 0.035-inch guidewire along the main duct through the minor duodenal papilla into the duodenum (Fig. 3). With the duodenoscope it was possible to grasp the guidewire and reposition it in the tail of the pancreas. We finally introduced a fully covered biliary self-expandable metallic stent (8 cm × 10mm) across the pancreaticoportal fistula.
Pancreaticoportal fistula and the main pancreatic duct stenosis (Fig. 4). Reported treatments for this condition range from conservative medical management to some variation of pancreatectomy [5]. Because of the rarity of the condition, there is a clear need for individualized treatment. In our patient, the insertion of the fully covered self-expandable metallic stent led to marked clinical improvement, reduction of serum amylase (389 U/L), and improvement of the abnormalities visible on MRI; these improvements were found to be persistent at 6-month follow-up.

Endoscopy_UCTN_Code_TTT_1AS_2AD

Competing interests: None

References

Rafael Kemp1, José C. Ardengh2, José E. Brunaldi3, Jorge Elias-Junior4, Valdair F. Muglia5, Leonor G. Savarese5, José S. dos Santos1

1 Department of Surgery and Anatomy, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil
2 University Hospital of the Ribeirão Preto School of Medicine, Department of Surgery and Anatomy, University of São Paulo, São Paulo, Brazil
3 University Hospital of the Ribeirão Preto School of Medicine, Department of Surgery and Anatomy, University of São Paulo, São Paulo, Brazil
4 Department of Internal Medicine, Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil
5 University Hospital of the Ribeirão Preto School of Medicine, Department of Internal Medicine, University of São Paulo, São Paulo, Brazil

Fig. 2 Endoscopic retrograde pancreatography (ERP) via the major duodenal papilla shows: a a pancreatic cystic collection with stenosis and dilatation of the main pancreatic duct and secondary ducts; b the guidewire passing into a pancreaticoportal fistula.

Fig. 3 a Endoscopic ultrasound (EUS) shows the 19G needle inside the main pancreatic duct. b EUS-guided pancreatography and the insertion of the guidewire. c Passage of the guidewire through the minor duodenal papilla.

Video 1 Treatment of pancreaticoportal fistula by endosonography-guided rendezvous.
Fig. 4  a Endoscopic view of the guidewire exiting the minor duodenal papilla. b Fluoroscopy shows insertion of the fully covered self-expanding metal stent (SEMS). c, d Follow-up magnetic resonance imaging (MRI) after 1 month shows the SEMS inside the main pancreatic duct (white arrow), and persistence of portal vein thrombosis but with a marked decrease in the caliber of the portal vein (arrowheads).